thalidomide has been researched along with Neoplasm Metastasis in 65 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients." | 9.17 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. ( Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E, 2013) |
| "This phase I trial assessed the maximal tolerated dose (MTD) of dacarbazine in combination with lenalidomide in metastatic melanoma." | 9.14 | Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. ( Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010) |
| "This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients." | 9.14 | Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009) |
| " The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma." | 9.14 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 9.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 9.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients." | 9.14 | Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma." | 9.12 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007) |
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 9.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer." | 9.12 | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. ( Colleoni, M; Ghisini, R; Goldhirsch, A; Maisonneuve, P; Nolè, F; Orlando, L; Peruzzotti, G; Rocca, A; Sandri, MT; Sanna, G; Viale, G; Zorzino, L, 2006) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer." | 9.09 | Phase II evaluation of thalidomide in patients with metastatic breast cancer. ( Baidas, SM; Crawford, JG; Fleming, GF; Flockhart, D; Hanfelt, J; Harris, L; Hawkins, MJ; Hayes, DF; Isaacs, C; Johnson, MD; Lippman, ME; Pluda, JM; Tefft, M; Winer, EP; Yamauchi, H, 2000) |
| "Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d." | 9.09 | Irinotecan and thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2000) |
| "Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma." | 7.73 | Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005) |
| "Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma." | 6.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 6.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 6.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "Patients with metastatic colorectal cancer are receiving 350 mg/m2 of irinotecan every 3 weeks plus 400 mg/m2/d of thalidomide." | 6.41 | Irinotecan/thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2002) |
| "Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors." | 5.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay." | 5.29 | The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996) |
| "This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients." | 5.17 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. ( Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E, 2013) |
| " The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma." | 5.14 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 5.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 5.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients." | 5.14 | Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients." | 5.14 | Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009) |
| "This phase I trial assessed the maximal tolerated dose (MTD) of dacarbazine in combination with lenalidomide in metastatic melanoma." | 5.14 | Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. ( Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010) |
| "The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases." | 5.12 | Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. ( Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM, 2006) |
| "Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma." | 5.12 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007) |
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 5.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer." | 5.12 | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. ( Colleoni, M; Ghisini, R; Goldhirsch, A; Maisonneuve, P; Nolè, F; Orlando, L; Peruzzotti, G; Rocca, A; Sandri, MT; Sanna, G; Viale, G; Zorzino, L, 2006) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer." | 5.09 | Phase II evaluation of thalidomide in patients with metastatic breast cancer. ( Baidas, SM; Crawford, JG; Fleming, GF; Flockhart, D; Hanfelt, J; Harris, L; Hawkins, MJ; Hayes, DF; Isaacs, C; Johnson, MD; Lippman, ME; Pluda, JM; Tefft, M; Winer, EP; Yamauchi, H, 2000) |
| "Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d." | 5.09 | Irinotecan and thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2000) |
| "Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma." | 3.73 | Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005) |
| "Twenty-six patients with advanced cancer (14 men/12 women), median age of 56 years (range 38-70 years), and a median number of two prior therapies (range 0-12) were enrolled." | 2.80 | Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. ( Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ, 2015) |
| "To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer." | 2.78 | Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. ( Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D, 2013) |
| " Intermittent dosing of pomalidomide allowed substantially higher doses than were previously reported with a continuous schedule." | 2.76 | A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. ( Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA, 2011) |
| " Lenalidomide was well tolerated up to a 35-mg/d intermittent dosing schedule at doses higher than previously indicated for hematologic malignancies." | 2.74 | Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ( Aragon-Ching, JB; Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Tohnya, TM; Ventiz, J; Woo, S; Wright, JJ, 2009) |
| "Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses." | 2.73 | Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. ( Campbell, J; Shah, MH; Varker, KA, 2008) |
| "Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma." | 2.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2." | 2.73 | A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008) |
| "Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days." | 2.73 | Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. ( Bacik, J; DeLuca, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Patel, PH; Russo, P; Schwartz, L, 2008) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 2.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Disease progression was observed in 24 patients (47%)." | 2.72 | Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. ( Amato, RJ; Morgan, M; Rawat, A, 2006) |
| " Pharmacokinetic data suggested a decreased metabolism of irinotecan into SN-38 and SN-38-glucuronide when it was administered with thalidomide." | 2.72 | Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ( Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G, 2006) |
| "Lenalidomide (LEN) is a structural and functional analogue of thalidomide that has demonstrated enhanced immunomodulatory properties and a more favorable toxicity profile." | 2.72 | Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. ( Baz, RC; Bukowski, RM; Choueiri, TK; Dreicer, R; Elson, P; Garcia, JA; Jinks, HA; Mekhail, TM; Rini, BI; Thakkar, SG, 2006) |
| "The treatment of advanced renal cell cancer remains unsatisfactory, therefore new combination regimens such as thalidomide and IL-2 are of interest." | 2.72 | Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. ( Bukowski, RM; Dreicer, R; Elson, P; Malhi, S; Mekhail, T; Olencki, T; Wood, L, 2006) |
| "Oral thalidomide was started at 200 mg/day and escalated after 2 days to 400 mg/day at week 0." | 2.71 | Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. ( Hegele, A; Heidenreich, A; Hofmann, R; Ohlmann, CH; Olbert, P; Schrader, AJ; Varga, Z; von Knobloch, R, 2005) |
| "Thalidomide was first given 100 mg/d for 1 week and 300 mg/d thereafter." | 2.71 | Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. ( Ahtinen, H; Bono, P; Hernberg, M; joensuu, H; Mäenpää, H; Virkkunen, P, 2003) |
| "The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease." | 2.70 | A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. ( Amato, R; Daliani, DD; Oliva, R; Pagliaro, L; Papandreou, CN; Perez, C; Thall, PF; Wang, X, 2002) |
| "Thalidomide was discontinued in 55 patients for lack of therapeutic response." | 2.70 | Thalidomide neuropathy in patients treated for metastatic prostate cancer. ( Culcea, E; Dahut, W; Figg, WD; Floeter, MK; Kruger, EA; Molloy, FM; Pluda, J; Reed, E; Sandbrink, F; Steinberg, SM; Syed, NA, 2001) |
| "Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma." | 2.46 | Advances in treatment for relapses and refractory multiple myeloma. ( Richards, T; Weber, D, 2010) |
| "Germ cell tumors are the most common malignancies in men under 50 years and also the most common cause of death from solid tumors in this age group." | 2.45 | Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. ( Albers, P; Christoph, F; Hinz, S; Hoepfner, M; Jung, K; Kempkensteffen, C; Krause, H; Lein, M; Miller, K; Schostak, M; Schrader, M; Stephan, C; Weikert, S, 2009) |
| "Thalidomide has significant neurotoxicity and its efficacy was not confirmed in recent studies." | 2.42 | Renal cell carcinoma: novel treatments for advanced disease. ( Heinzer, H; Huland, E, 2003) |
| "Several promising approaches to the treatment of renal cancer have been developed over recent years." | 2.41 | [Metastatic kidney cancer: new therapeutic approaches]. ( Escudier, B; Mejean, A; Negrier, S; Oudard, S, 2002) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 2.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "Thalidomide, which was developed as a nonbarbiturate sedative agent, was taken off the market in 1961 after it was linked to a spate of major birth defects." | 2.41 | Thalidomide: new indications? ( Combe, B, 2001) |
| "Patients with metastatic colorectal cancer are receiving 350 mg/m2 of irinotecan every 3 weeks plus 400 mg/m2/d of thalidomide." | 2.41 | Irinotecan/thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2002) |
| "Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors." | 1.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "In addition, an in vivo experimental metastasis model also showed that treatment with the drugs resulted in a significantly lower number of metastatic pulmonary nodules relative to control mice." | 1.35 | Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). ( Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B, 2009) |
| "Oral thalidomide was started at 200 mg/d and escalated after two days to 400 mg/d at week 0." | 1.33 | [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. ( Hegele, A; Heidenreich, A; Hofmann, R; Olbert, P; Schrader, AJ; Varga, Z, 2006) |
| "Thalidomide has demonstrated clinical activity in various malignancies including androgen-independent prostate cancer." | 1.32 | Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. ( Eger, K; Figg, WD; Gütschow, M; MacPherson, GR; Ng, SS, 2004) |
| "Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay." | 1.29 | The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.62) | 18.2507 |
| 2000's | 45 (69.23) | 29.6817 |
| 2010's | 17 (26.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sundaresan, L | 1 |
| Kumar, P | 1 |
| Chatterjee, S | 1 |
| Prince, SK | 1 |
| Forgeson, G | 1 |
| Siena, S | 1 |
| Van Cutsem, E | 1 |
| Li, M | 1 |
| Jungnelius, U | 1 |
| Romano, A | 1 |
| Beck, R | 1 |
| Bencardino, K | 1 |
| Elez, ME | 1 |
| Prenen, H | 1 |
| Sanchis, M | 1 |
| Sartore-Bianchi, A | 1 |
| Tejpar, S | 1 |
| Gandhi, A | 1 |
| Shi, T | 1 |
| Tabernero, J | 1 |
| Broccoli, A | 1 |
| Pellegrini, C | 1 |
| Celli, M | 1 |
| Argnani, L | 1 |
| Agostinelli, C | 1 |
| Pileri, S | 1 |
| Zinzani, PL | 1 |
| Agarwal, N | 1 |
| Apolo, AB | 1 |
| Tsao, CK | 1 |
| Lee, KM | 1 |
| Godbold, JH | 1 |
| Soto, R | 1 |
| Poole, A | 1 |
| Gimpel-Tetra, K | 1 |
| Lowe, N | 1 |
| Oh, WK | 1 |
| Galsky, MD | 1 |
| Bilen, MA | 1 |
| Fu, S | 1 |
| Falchook, GS | 1 |
| Ng, CS | 1 |
| Wheler, JJ | 1 |
| Abdelrahim, M | 1 |
| Erguvan-Dogan, B | 1 |
| Hong, DS | 1 |
| Tsimberidou, AM | 1 |
| Kurzrock, R | 1 |
| Naing, A | 1 |
| Leuci, V | 1 |
| Maione, F | 1 |
| Rotolo, R | 1 |
| Giraudo, E | 1 |
| Sassi, F | 1 |
| Migliardi, G | 1 |
| Todorovic, M | 1 |
| Gammaitoni, L | 1 |
| Mesiano, G | 1 |
| Giraudo, L | 1 |
| Luraghi, P | 1 |
| Leone, F | 1 |
| Bussolino, F | 1 |
| Grignani, G | 1 |
| Aglietta, M | 1 |
| Trusolino, L | 1 |
| Bertotti, A | 1 |
| Sangiolo, D | 1 |
| Lu, L | 1 |
| Payvandi, F | 1 |
| Wu, L | 1 |
| Zhang, LH | 1 |
| Hariri, RJ | 1 |
| Man, HW | 1 |
| Chen, RS | 1 |
| Muller, GW | 1 |
| Hughes, CC | 1 |
| Stirling, DI | 1 |
| Schafer, PH | 1 |
| Bartlett, JB | 2 |
| Schrader, M | 1 |
| Kempkensteffen, C | 1 |
| Christoph, F | 1 |
| Hinz, S | 1 |
| Weikert, S | 1 |
| Lein, M | 1 |
| Krause, H | 1 |
| Stephan, C | 1 |
| Jung, K | 1 |
| Hoepfner, M | 1 |
| Albers, P | 1 |
| Miller, K | 1 |
| Schostak, M | 1 |
| Dahut, WL | 3 |
| Aragon-Ching, JB | 1 |
| Woo, S | 1 |
| Tohnya, TM | 2 |
| Gulley, JL | 2 |
| Arlen, PM | 2 |
| Wright, JJ | 2 |
| Ventiz, J | 1 |
| Figg, WD | 5 |
| Ott, PA | 1 |
| Chang, JL | 1 |
| Oratz, R | 1 |
| Jones, A | 1 |
| Farrell, K | 1 |
| Muggia, F | 1 |
| Pavlick, AC | 1 |
| Liu, WM | 1 |
| Henry, JY | 1 |
| Meyer, B | 1 |
| Dalgleish, AG | 1 |
| Galustian, C | 1 |
| Ning, YM | 1 |
| Glaspy, J | 2 |
| Atkins, MB | 1 |
| Richards, JM | 1 |
| Agarwala, SS | 1 |
| O'Day, S | 1 |
| Knight, RD | 3 |
| Jungnelius, JU | 2 |
| Bedikian, AY | 1 |
| Eisen, T | 1 |
| Trefzer, U | 1 |
| Hamilton, A | 1 |
| Hersey, P | 1 |
| Millward, M | 1 |
| Clark, JI | 2 |
| Moon, J | 2 |
| Hutchins, LF | 2 |
| Sosman, JA | 1 |
| Kast, WM | 1 |
| Da Silva, DM | 1 |
| Liu, PY | 1 |
| Thompson, JA | 2 |
| Flaherty, LE | 2 |
| Sondak, VK | 2 |
| Burris, HA | 3 |
| Jones, SF | 2 |
| Shipley, D | 1 |
| Meluch, AA | 1 |
| Greco, FA | 1 |
| Barton, JH | 1 |
| Yardley, DA | 2 |
| Hainsworth, JD | 3 |
| Richards, T | 1 |
| Weber, D | 1 |
| Hwu, WJ | 2 |
| Patnana, M | 1 |
| Bassett, R | 1 |
| Papadopoulos, NE | 1 |
| Kim, KB | 1 |
| Hwu, P | 1 |
| Bedikian, A | 1 |
| Infante, JR | 2 |
| Bendell, JC | 2 |
| Spigel, DR | 2 |
| Weekes, CD | 1 |
| Messersmith, WA | 1 |
| Shenoy, SK | 1 |
| Han, S | 1 |
| Zhao, YL | 1 |
| Hara, MR | 1 |
| Oliver, T | 1 |
| Cao, Y | 1 |
| Dewhirst, MW | 1 |
| Park, B | 1 |
| Sung, B | 1 |
| Yadav, VR | 1 |
| Chaturvedi, MM | 1 |
| Aggarwal, BB | 1 |
| Shukla, N | 1 |
| Kobos, R | 1 |
| Renaud, T | 1 |
| Teruya-Feldstein, J | 1 |
| Price, A | 1 |
| McAllister-Lucas, L | 1 |
| Steinherz, P | 1 |
| Arkenau, HT | 1 |
| Rubin, MS | 1 |
| Waterhouse, D | 1 |
| Jones, GT | 1 |
| Lane, CM | 1 |
| Daliani, DD | 1 |
| Papandreou, CN | 1 |
| Thall, PF | 1 |
| Wang, X | 1 |
| Perez, C | 1 |
| Oliva, R | 1 |
| Pagliaro, L | 1 |
| Amato, R | 2 |
| Negrier, S | 1 |
| Mejean, A | 1 |
| Oudard, S | 1 |
| Escudier, B | 1 |
| Mall, JW | 1 |
| Philipp, AW | 1 |
| Mall, W | 1 |
| Pollmann, C | 1 |
| Danson, S | 1 |
| Lorigan, P | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Ranson, M | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 1 |
| Middleton, MR | 1 |
| Hernberg, M | 1 |
| Virkkunen, P | 1 |
| Bono, P | 1 |
| Ahtinen, H | 1 |
| Mäenpää, H | 1 |
| joensuu, H | 1 |
| Huland, E | 1 |
| Heinzer, H | 1 |
| Sparano, JA | 1 |
| Gray, R | 1 |
| Giantonio, B | 1 |
| O'Dwyer, P | 1 |
| Comis, RL | 1 |
| Gulley, J | 1 |
| Dahut, W | 2 |
| Ng, SS | 2 |
| Parker, C | 1 |
| Zeldis, J | 1 |
| MacPherson, GR | 1 |
| Gütschow, M | 1 |
| Eger, K | 1 |
| Zhang, ZL | 1 |
| Liu, ZS | 1 |
| Sun, Q | 1 |
| Schrader, AJ | 2 |
| Heidenreich, A | 2 |
| Hegele, A | 2 |
| Olbert, P | 2 |
| Ohlmann, CH | 1 |
| Varga, Z | 2 |
| von Knobloch, R | 1 |
| Hofmann, R | 2 |
| Colleoni, M | 2 |
| Orlando, L | 1 |
| Sanna, G | 1 |
| Rocca, A | 2 |
| Maisonneuve, P | 2 |
| Peruzzotti, G | 2 |
| Ghisini, R | 1 |
| Sandri, MT | 2 |
| Zorzino, L | 2 |
| Nolè, F | 1 |
| Viale, G | 1 |
| Goldhirsch, A | 1 |
| McCollum, AD | 1 |
| Wu, B | 1 |
| Clark, JW | 1 |
| Kulke, MH | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Earle, CC | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
| Amato, RJ | 3 |
| Morgan, M | 1 |
| Rawat, A | 1 |
| Allegrini, G | 1 |
| Di Paolo, A | 1 |
| Cerri, E | 1 |
| Cupini, S | 1 |
| Amatori, F | 1 |
| Masi, G | 1 |
| Danesi, R | 1 |
| Marcucci, L | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Falcone, A | 1 |
| Olencki, T | 1 |
| Malhi, S | 1 |
| Mekhail, T | 1 |
| Dreicer, R | 2 |
| Elson, P | 2 |
| Wood, L | 1 |
| Bukowski, RM | 2 |
| Mita, MM | 1 |
| Rowinsky, EK | 1 |
| Forero, L | 1 |
| Eckhart, SG | 1 |
| Izbicka, E | 1 |
| Weiss, GR | 1 |
| Beeram, M | 1 |
| Mita, AC | 1 |
| de Bono, JS | 1 |
| Tolcher, AW | 1 |
| Hammond, LA | 1 |
| Simmons, P | 1 |
| Berg, K | 1 |
| Takimoto, C | 1 |
| Patnaik, A | 1 |
| Rick, O | 1 |
| Braun, T | 1 |
| Siegert, W | 1 |
| Beyer, J | 1 |
| Tannir, N | 1 |
| Jonasch, E | 1 |
| Pagliaro, LC | 1 |
| Mathew, P | 1 |
| Siefker-Radtke, A | 1 |
| Rhines, L | 1 |
| Lin, P | 1 |
| Tibbs, R | 1 |
| Do, KA | 1 |
| Lin, SH | 1 |
| Tu, SM | 1 |
| Alikunju, S | 1 |
| Pillarisetti, S | 1 |
| Choueiri, TK | 1 |
| Rini, BI | 1 |
| Garcia, JA | 1 |
| Thakkar, SG | 1 |
| Baz, RC | 1 |
| Mekhail, TM | 1 |
| Jinks, HA | 1 |
| Johansson, HA | 1 |
| Salvatici, M | 1 |
| Passerini, R | 1 |
| Laber, DA | 1 |
| Khan, MI | 1 |
| Kloecker, GH | 1 |
| Schonard, C | 1 |
| Taft, BS | 1 |
| Salvador, C | 1 |
| Varker, KA | 1 |
| Campbell, J | 1 |
| Shah, MH | 1 |
| Solti, M | 1 |
| Berd, D | 1 |
| Mastrangelo, MJ | 1 |
| Sato, T | 1 |
| Khan, M | 1 |
| Lange, MK | 1 |
| Patel, PH | 1 |
| Kondagunta, GV | 1 |
| Schwartz, L | 1 |
| Ishill, N | 1 |
| Bacik, J | 1 |
| DeLuca, J | 1 |
| Russo, P | 1 |
| Motzer, RJ | 1 |
| Mohammad, T | 1 |
| Minchinton, AI | 1 |
| Fryer, KH | 1 |
| Wendt, KR | 1 |
| Clow, KA | 1 |
| Hayes, MM | 1 |
| Ono, M | 1 |
| Kuwano, M | 1 |
| Bruera, E | 1 |
| Neumann, CM | 1 |
| Pituskin, E | 1 |
| Calder, K | 1 |
| Ball, G | 1 |
| Hanson, J | 1 |
| Baidas, SM | 1 |
| Winer, EP | 1 |
| Fleming, GF | 1 |
| Harris, L | 1 |
| Pluda, JM | 1 |
| Crawford, JG | 1 |
| Yamauchi, H | 1 |
| Isaacs, C | 1 |
| Hanfelt, J | 1 |
| Tefft, M | 1 |
| Flockhart, D | 1 |
| Johnson, MD | 1 |
| Hawkins, MJ | 1 |
| Lippman, ME | 1 |
| Hayes, DF | 1 |
| Govindarajan, R | 2 |
| Molloy, FM | 1 |
| Floeter, MK | 1 |
| Syed, NA | 1 |
| Sandbrink, F | 1 |
| Culcea, E | 1 |
| Steinberg, SM | 1 |
| Pluda, J | 1 |
| Kruger, EA | 1 |
| Reed, E | 1 |
| Combe, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer[NCT01032291] | Phase 2 | 51 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to A business decision not to continue with Phase 2b based on non-safety observations during proof of concept phase.) | ||
| Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma[NCT01342172] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2011-03-31 | Terminated (stopped due to low accrual) | ||
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer[NCT00031941] | Phase 1 | 0 participants | Interventional | 2002-04-30 | Completed | ||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy[NCT00057616] | Phase 3 | 274 participants | Interventional | 2002-10-01 | Completed | ||
| A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988] | Phase 2 | 64 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer[NCT00193102] | Phase 2 | 40 participants (Anticipated) | Interventional | 2001-04-30 | Terminated | ||
| Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy[NCT00179608] | Phase 1 | 28 participants | Interventional | 2005-09-01 | Completed | ||
| A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas[NCT00540579] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II[NCT00026520] | Phase 2 | 0 participants | Interventional | 2001-11-30 | Completed | ||
| Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen[NCT00096525] | Phase 2 | 0 participants | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period:~If <2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg.~If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide.~If <2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg.~If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide.~If <2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg.~If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators." (NCT01032291)
Timeframe: Up to Day 28 (Cycle 1)
| Intervention | participants (Number) |
|---|---|
| Lenalidomide Plus Cetuximab (Safety Lead-in) | 1 |
"Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009).~Complete response-disappearance of all lesions~Partial response-30% decrease in the sum of diameters of target lesions from baseline~Stable disease-neither shrinkage nor increase of lesions.~Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.~Participants with evidence of objective tumor response have the response confirmed with repeat assessments performed at the next scheduled scan." (NCT01032291)
Timeframe: Week 9 up to week 24
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Response Not Evaluable | |
| Lenalidomide (Proof of Concept) | 0 | 0 | 3 | 13 | 5 |
| Lenalidomide Plus Cetuximab (Proof of Concept) | 0 | 0 | 5 | 13 | 3 |
TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE. (NCT01032291)
Timeframe: up to week 28
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=1 TEAE | Serious TEAE | TEAE leading to discontinuing lenalidomide | TEAE leading to discontinuing cetuximab | TEAE leading to reduction/interruption of lenalido | TEAE leading to reduction/interruption of cetuxima | TEAE related to lenalidomide | TEAE related to cetuximab | TEAE NCI CTC grade 3 or higher | TEAE NCI CTC grade 3+ related to lenalidomide | TEAE NCI CTC grade 3+ related to cetuximab | Serious TEAE related to lenalidomide | Serious TEAE related to cetuximab | |
| Lenalidomide (Proof of Concept) | 20 | 9 | 7 | NA | 6 | NA | 9 | NA | 13 | 4 | NA | 0 | NA |
| Lenalidomide Plus Cetuximab (Proof of Concept) | 21 | 9 | 5 | 6 | 9 | 7 | 13 | 19 | 12 | 4 | 7 | 2 | 2 |
| Lenalidomide Plus Cetuximab (Safety Lead-In) | 8 | 5 | 3 | 3 | 2 | 1 | 5 | 8 | 4 | 3 | 2 | 2 | 2 |
MTD was determined by testing planned increasing doses up to 25 mg daily dose on days 1-14, starting at 10mg. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in > 33% of participants. DLTs were defined as any lenalidomide-related Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0) Grade 3 or 4 adverse events (NCT01342172)
Timeframe: after 1 cycle (each cycle is 21 days)
| Intervention | mg (Number) |
|---|---|
| Lenalidomide | 10 |
"Best Overall Response to evaluate lenalidomide as maintenance treatment in patients achieving an objective response of either complete response or partial response following completion of 6 cycles of combination therapy.~Complete Response (CR) - CR of target lesions and no new lesions Partial Response (PR) -PR of target lesions and no new lesions Stable Disease (SD) - SD of target lesions and no new lesions Progression Disease (PD) - any status of target lesions and new lesions" (NCT01342172)
Timeframe: 168 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| CR | PR | |
| Lenalidomide | 1 | 2 |
Number of grade >=3 adverse events to assess the safety of combination therapy with gemcitabine, cisplatin plus lenalidomide as determined by the frequency and severity of adverse events as per the NCI Common Terminology for Adverse Events (CTCAE) version 4.0. (NCT01342172)
Timeframe: Day 1 and Day 8 of each treatment cycle; 21 days after the last dose of Lenalidomide
| Intervention | events (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| Lenalidomide | 28 | 7 |
"The objective response rate as determined by Response Evaluation Criteria in Solid Tumors (RECIST).~Complete Response (CR) Disappearance of all target lesions for a period of at least one month.~Partial Response (PR) At least a 30% decrease in the sum of the longest diameter of measures lesions (target lesions), taking as reference the baseline sum of the longest diameter.~Stable Disease (NR/SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since the treatment started.~Progressive Disease (PD) A 20% or greater increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT01342172)
Timeframe: After 2 cycles (a cycle is 21 days)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| CR | PR | SD | PD | not evaluable | |
| Lenalidomide | 1 | 2 | 3 | 2 | 1 |
The relative incidence of Grade 3/4 adverse events from protocol treatment as defined by Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (NCT00540579)
Timeframe: 24 Months
| Intervention | percentage of patients (Number) |
|---|---|
| Pomalidomide/Gemcitabine | 39 |
"Unacceptable side effects or dose-limiting toxicities (DLTs) were defined as follows:~Inability to Complete cycle 1 of therapy due to drug-related toxicity.~> Grade 3 non-hematological drug-related toxicity (excluding alopecia) despite optimal supportive care~Febrile neutropenia (absolute neutrophil count [ANC] <1,000/μL and fever >101° F (38.5° C))~Grade 4 neutropenia that occurs prior to day 21. (Grade 4 neutropenia that occurs after day 21 but resolves within 7 days of the scheduled cycle 2, will not be considered DLT)~Platelet count < 25,000/μL~Inability to initiate Cycle 2, Day 1 therapy within 7 days of scheduled start (i.e. cannot delay the start of Cycle 2 by more than 7 days following the normal 7 day recovery period) due to drug-related toxicity." (NCT00540579)
Timeframe: 6 months
| Intervention | milligrams (Number) | |
|---|---|---|
| Pomalidomide | Gemcitabine | |
| Pomalidomide/Gemcitabine | 10 | 1000 |
10 reviews available for thalidomide and Neoplasm Metastasis
| Article | Year |
|---|---|
Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell | 2009 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; | 2010 |
[Metastatic kidney cancer: new therapeutic approaches].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Kidney Neoplasms; Neoplasm Metastasis; Neopl | 2002 |
Renal cell carcinoma: novel treatments for advanced disease.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Renal Cell; Combined Moda | 2003 |
Novel clinical trials in androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; | 2002 |
Selected players in the inflammation cascade and drugs that target these inflammation genes against metastasis.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Glucuronidase; Humans; Inflammation; Macrophages; Matr | 2006 |
[Neovascularization and tumor development].
Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatin | 1998 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
Thalidomide: new indications?
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Humans; Multiple Myeloma; Neoplasm Metastasis; Neov | 2001 |
Irinotecan/thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Che | 2002 |
37 trials available for thalidomide and Neoplasm Metastasis
| Article | Year |
|---|---|
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2013 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Rela | 2014 |
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L | 2015 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lenalidomi | 2009 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2010 |
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Respo | 2010 |
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Dru | 2011 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2013 |
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Surv | 2002 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug | 2003 |
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Topics: Administration, Oral; Humans; Lenalidomide; Male; Neoplasm Metastasis; Palliative Care; Prostatic Ne | 2004 |
Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit | 2005 |
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineo | 2006 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2006 |
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2006 |
Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2006 |
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug; | 2007 |
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neopla | 2006 |
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imm | 2006 |
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoid Tumor; Chrom | 2008 |
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma | 2007 |
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kid | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2008 |
Thalidomide in patients with cachexia due to terminal cancer: preliminary report.
Topics: Aged; Appetite; Cachexia; Female; Humans; Hypnotics and Sedatives; Male; Neoplasm Metastasis; Neopla | 1999 |
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Breast Neoplasms; Drug Administration Schedule; Endothelial Gr | 2000 |
Irinotecan and thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Che | 2000 |
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Topics: Action Potentials; Age Factors; Aged; Aged, 80 and over; Brachial Plexus; Cohort Studies; Dose-Respo | 2001 |
18 other studies available for thalidomide and Neoplasm Metastasis
| Article | Year |
|---|---|
Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cholesterol; Gene | 2018 |
Bleeding from gastrointestinal tract recurrence of non-seminomatous germ cell tumour testis, showing temporary response to gemcitabine and oxaliplatin chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gastrointestinal Hemorrhage; G | 2013 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2014 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Hel | 2009 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; | 2009 |
Reversal of docetaxel resistance with bevacizumab and thalidomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; | 2012 |
Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Diterpenes; Enzyme Inhibitors; Epoxy Compounds | 2011 |
Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, | 2012 |
Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Small Cell; Female; Humans; Neoplasm Metastasis; Survivors | 2002 |
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Co | 2004 |
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Humans; Immunoh | 2004 |
Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Division; DNA Prime | 2005 |
Activity of thalidomide in patients with platinum-refractory germ-cell tumours.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Gonadal Disorders; Humans; Mediastinal Neop | 2006 |
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2006 |
The effect of thalidomide on experimental tumors and metastases.
Topics: Animals; Combined Modality Therapy; Female; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Neov | 1996 |
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com | 2000 |